Author/Authors :
Nikandish, Reza Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Zand, Farid Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Sabetian, Golnar Trauma Research Center - Shiraz University of Medical Sciences , Faghihi, Hajar Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Masjedi, Mansour Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Maghsoudi, Behzad Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Vazin, Afsaneh Department of Clinical Pharmacy - Faculty of Pharmacy - Shiraz University of Medical Sciences , Ghorbani, Mohammad Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences , Asadpour, Elham Anesthesiology and Critical Care Research Center - Shiraz University of Medical Sciences
Abstract :
Aim: Prophylaxis against stress ulcer in mechanically ventilated patients is one of the causes for ventilator‑associated pneumonia (VAP).
Our aim was evaluating the effect of intravenous pantoprazole and ranitidine in the incidence of VAP in critically ill patients.
Materials and Methods: Patients with at least 48 h of expected mechanical ventilation were allocated randomly to receive either 50 mg
ranitidine (R) every 8 h or 40 mg pantoprazole (P) every 12 h intravenously from admission. VAP diagnosis was according to the Clinical
Pneumonia Infection Score and positive culture. Results: Eighty‑six patients during a 15‑month period were analyzed; the study showed a low
difference between VAP incidence in the ranitidine and pantoprazole groups. No significant difference was observed in terms of gastrointestinal
bleeding, intensive care unit, hospital length of stay, and mortality between the groups. Conclusion: VAP incidence is hardly related to the
type of stress ulcer prophylaxis agent with a high rate of VAP and low utilization of VAP prophylaxis bundle.
